Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.
Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...
New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...
Users of Ozempic and other drugs are shunning items like energy drinks and salty snacks, research shows. But there are ...
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...